A seismic shift is underway across the American industrial landscape, where an unprecedented surge of capital is fueling the rapid expansion of facilities designed to produce the next generation of life-saving medicines. This article analyzes the unprecedented surge in U.S. biomanufacturing
A quiet but monumental shift is reshaping the foundations of the pharmaceutical industry, driven by a convergence of unprecedented demand for new therapies and the fragile realities of a globally interconnected supply chain. Eli Lilly and Company is at the forefront of this transformation,
The Dawn of a Biomanufacturing Boom A wave of unprecedented capital is reshaping the American industrial landscape, signaling the start of a biomanufacturing investment super-cycle that promises to redefine domestic production for decades to come. An analysis of recent investment trends reveals a
A New Frontier in National Security: The Dawn of Intelligent Manufacturing The intricate web of global supply chains, once a symbol of efficiency, now represents a critical vulnerability for the United States' defense industrial base. Recent geopolitical shifts have exposed the risks of relying on
A single scheduled review of a continental trade pact has rapidly unraveled the typically cordial relationship between the United States and Canada, revealing deep-seated frictions that extend far beyond mere economic policy. The impending talks over the United States–Mexico–Canada Agreement
In a decisive pivot toward domestic supply chain security, Swiss contract development and manufacturing organization Siegfried is making a significant move to solidify its foothold in the United States, announcing a series of acquisitions designed to bolster its small-molecule drug substance
